<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38007044</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8227</ISSN><JournalIssue CitedMedium="Internet"><Volume>207</Volume><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Diabetes research and clinical practice</Title><ISOAbbreviation>Diabetes Res Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Quantitative sensory testing defines the trajectory of sensory neuropathy after severe COVID-19.</ArticleTitle><Pagination><StartPage>111029</StartPage><MedlinePgn>111029</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabres.2023.111029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0168-8227(23)00792-1</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess sensory neuropathy development after severe COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with severe COVID-19 underwent assessment of neuropathic symptoms, tendon reflexes, and quantitative sensory testing to evaluate vibration (VPT), cold (CPT), warm (WPT) and heat perception thresholds (HPT) within 1-3&#xa0;weeks of admission and after 1-year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">32 participants with severe COVID-19 aged 68.6&#xa0;&#xb1;&#xa0;12.4 (18.8&#xa0;% diabetes) were assessed. At baseline, numbness and neuropathic pain were present in 56.3&#xa0;% and 43.8&#xa0;% of participants, respectively. On the feet, VPT, WPT, and HPT were abnormal in 81.3&#xa0;%, CPT was abnormal in 50.0&#xa0;% and HPT on the face was abnormal in 12.5&#xa0;% of patients. At 1-year follow-up, the prevalence of abnormal VPT (81.3&#xa0;% vs 50.0&#xa0;%, P&#xa0;&lt;&#xa0;0.01), WPT (81.3&#xa0;% vs 43.8&#xa0;%, P&#xa0;&lt;&#xa0;0.01), and HPT (81.3&#xa0;% vs 50.0&#xa0;%, P&#xa0;&lt;&#xa0;0.01) decreased, with no change in CPT (P&#xa0;=&#xa0;0.21) on the feet or HPT on the face (P&#xa0;=&#xa0;1.0). Only participants without diabetes recovered from an abnormal VPT, CPT, and WPT. Patients with long-COVID (37.5&#xa0;%) had comparable baseline VPT, WPT and CPT with those without long-COVID (P&#xa0;=&#xa0;0.07-0.69).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Severe COVID-19 is associated with abnormal vibration and thermal thresholds which are sustained for up to 1&#xa0;year in patients with diabetes. Abnormal sensory thresholds have no association with long-COVID development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ponirakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odriozola</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain. Electronic address: ariel_16oo@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Luc&#xed;a</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Lidia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odriozola</LastName><ForeName>Samantha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Phi Med Europe SL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrens</LastName><ForeName>Ainhoa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coroleu</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ponce</LastName><ForeName>Meritxell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meije</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemente</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital of Barcelona SCIAS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odriozola</LastName><ForeName>Maria B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Phi Med Europe SL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Rayaz A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Diabetes Res Clin Pract</MedlineTA><NlmUniqueID>8508335</NlmUniqueID><ISSNLinking>0168-8227</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012684" MajorTopicYN="N">Sensory Thresholds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="Y">Neuralgia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014732" MajorTopicYN="N">Vibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003929" MajorTopicYN="Y">Diabetic Neuropathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Neuropathy</Keyword><Keyword MajorTopicYN="N">Quantitative sensory testing</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Phi Med Europe S.L. provided the NerveCheck Master device and funded the study. M.N. Odriozola, S. Odriozola, M.B. Odriozola and A. Odriozola are the owners and inventors of the NerveCheck Master. We declare that we have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship and are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>26</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>25</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38007044</ArticleId><ArticleId IdType="doi">10.1016/j.diabres.2023.111029</ArticleId><ArticleId IdType="pii">S0168-8227(23)00792-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>